The Effect of SARS-CoV-2 Virus Infection on the Course of Atopic Dermatitis in Patients
Abstract
:1. Introduction
2. Materials and Methods
2.1. RT-PCR Diagnostics
2.2. Statistics
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Braun-Falco, O.; Burgdorf, W.H.C.; Plewig, G.; Wolff, H.H.; Landthaler, M. Dermatology, 3rd ed.; Springer: Heidelberg, Germany, 2009; pp. 230–298. [Google Scholar]
- Nowicki, J.R.; Majewski, S. Dermatologia i Choroby Przenoszone Drogą Płciową; PZWL: Warszawa, Poland, 2019; pp. 1–98. [Google Scholar]
- Simon, D.; Bieber, T. Systemic therapy for atopic dermatitis. Allergy 2014, 69, 46–55. [Google Scholar] [CrossRef] [PubMed]
- Barbarot, S.; Auziere, S.; Gadkari, A. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy 2018, 73, 1284–1293. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nettis, E.; MOrtoncelli, M.; GPellacani, G.; Foti, C.; Di Leo, E.; Patruno, C.; Rongioletti, F.; Argenziano, G.; Ferrucci, S.M.; Macchia, L.; et al. A Multicenter Study on the Prevalence of Clinical Patterns and Clinical Phenotypes in Adult Atopic Dermatitis. J. Investig. Allergol. Clin. Immunol. 2020, 30, 448–450. [Google Scholar] [CrossRef]
- Dattola, A.; Bennardo, L.; Silvestri, M.; Nisticò, S.P. What’s new in the treatment of atopic dermatitis? Dermatol. Ther. 2019, 32, e12787. [Google Scholar] [CrossRef] [PubMed]
- David Boothe, W.; Tarbox, J.A.; Tarbox, M.B. Atopic Dermatitis: Pathophysiology. In Management of Atopic Dermatitis; Fortson, E., Feldman, S., Strowd, L., Eds.; Advances in Experimental Medicine and Biology; Springer: Heidelberg, Germany, 2017; pp. 21–37. [Google Scholar]
- Weidinger, S.; Novak, N. Atopic dermatitis. Lancet 2016, 387, 1109–1122. [Google Scholar] [CrossRef]
- Nowicki, J.R.; Trzeciak, M.; Kaczmarski, M.; Wilkowska, A.; Czarnecka-Operacz, M.; Kowalewski, C. Atopowe zapalenie skóry. Interdyscyplinarne zalecenia diagnostyczne i terapeutyczne Polskiego Towarzystwa Dermatologicznego, Polskiego Towarzystwa Alergologicznego, Polskiego Towarzystwa Pediatrycznego i Polskiego Towarzystwa Medycyny Rodzinnej. Część I. Profilaktyka, leczenie miejscowe i fototerapia. Przegl. Dermatol. 2019, 106, 354–374. [Google Scholar]
- Equoral w atopowym zapaleniu skóry. Available online: http://leki.urpl.gov.pl/files/25_Equoral_kap_ela_25_50_100.pdf (accessed on 10 March 2021).
- Wollenberg, A.; Barbarot, S.; Bieber, T.; Christen-Zaech, S.; Deleuran, M.; Fink-Wagner, A.; Gieler, U.; Girolomoni, G.; Lau, S.; Muraro, A.; et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part II. J. Eur. Acad. Dermatol. Venereol. 2018, 32, 850–878. [Google Scholar] [CrossRef] [Green Version]
- Seegräber, M.; Srour, J.; Walter, A.; Knop, M.; Wollenberg, A. Dupilumab for treatment of atopic dermatitis. Expert Rev. Clin. Pharmacol. 2018, 11, 467–474. [Google Scholar] [CrossRef] [PubMed]
- COVID-19—Global Situation. Available online: https://covid19.who.int/ (accessed on 1 January 2021).
- Guan, W.J.; Liang, W.H.; Zhao, Y.; Liang, H.R.; Chen, Z.S.; Li, Y.M. Comorbidity and its impact on 1590 patients with Covid-19 in China: A nationwide analysis. Eur. Respir. J. 2020, 55, 45–48. [Google Scholar] [CrossRef] [Green Version]
- Akyima, S.; Hamdeh, S.; Micic, D.; Sakuraba, A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: A systematic review and meta-analysis. Ann. Rheum. Dis. 2021, 80, 384–391. [Google Scholar] [CrossRef]
- Talamonti, M.; Galluzzo, M.; Chiricozzi, A.; Quaglino, P.; Fabbrocini, G.; Gisondi, P.; Marzano, A.V.; Potenza, C.; Conti, A.; Parodi, A.; et al. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opin. Biol. Ther. 2021, 21, 271–277. [Google Scholar] [CrossRef] [PubMed]
- Sadeghinia, A.; Daneshpazhooh, M. Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review. Dermatol. Ther. 2021, 34, 23–29. [Google Scholar] [CrossRef]
- Klimek, L.; Pfaar, O.; Worm, M.; Eiwegger, T.; Hagemann, J.; Ollert, M.; Untersmayr, E.; Hoffmann-Sommergruber, K.; Vultaggio, K.; Ollert, M.; et al. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA), Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI), Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI), Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI), Österreichische Gesellschaft für Pneumologie (ÖGP) in co-operation with the German, Austrian, and Swiss ARIA groups, and the European Academy of Allergy and Clinical Immunology (EAACI). Allergol. Sel. 2020, 4, 53–68. [Google Scholar] [CrossRef]
- Ricardo, J.W.; Lipner, S.R. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol. Ther. 2020, 33, 19–23. [Google Scholar] [CrossRef] [PubMed]
- Buhl, T.; Beissert, S.; Gaffal, E.; Goebeler, M.; Hertl, M.; Mauch, C.; Reich, K.; Schmidt, E.; Schön, M.P.; Sticherling, M.; et al. COVID-19 and implications for dermatological and allergological diseases. J. Dtsch. Dermatol. Ges. 2020, 18, 815–824. [Google Scholar] [CrossRef] [PubMed]
- Elmas, Ö.F.; Demirbaş, A.; Kutlu, Ö.; Bağcıer, F.; Metin, M.S.; Özyurt, K.; Akdeniz, N.; Atasoy, M.; Türsen, Ü.; Lotti, T. Psoriasis and COVID-19: A narrative review with treatment considerations. Dermatol. Ther. 2020, 33, 7–16. [Google Scholar] [CrossRef]
- Seirafianpour, F.; Sodagar, S.; Pour Mohammad, A.; Panahi, P.; Mozafarpoor, S.; Almasi, S. Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review. Dermatol. Ther. 2020, 33, 230–245. [Google Scholar] [CrossRef]
- Nobari, N.N.; Goodarzi, A. Patients with specific skin disorders who are affected by COVID-19: What do experiences say about management strategies? A systematic review. Dermatol. Ther. 2020, 33, 248–250. [Google Scholar] [CrossRef] [PubMed]
- Amerio, P.; Prignano, F.; Giuliani, F.; Gualdi, G. COVID-19 and psoriasis: Should we fear for patients treated with biologics? Dermatol. Ther. 2020, 33, 16–21. [Google Scholar] [CrossRef] [Green Version]
- Brownstone, N.D.; Thibodeaux, Q.G.; Reddy, V.D.; Myers, B.A.; Chan, S.Y.; Bhutani, T.; Liao, W. Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Dermatol. Ther. 2020, 10, 881–885. [Google Scholar] [CrossRef]
- Ferrucci, S.; Romagnuolo, M.; Angileri, L.; Berti, E.; Tavecchio, S. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: Two case reports. J. Eur. Acad. Dermatol. Venereol. 2020, 34, e303–e304. [Google Scholar] [CrossRef]
- Yang, J.M.; Koh, H.Y.; Moon, S.Y. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J. Allergy Clin. Immunol. 2020, 146, 790–798. [Google Scholar] [CrossRef] [PubMed]
- Weidinger, S.; Beck, L.A.; Bieber, T. Atopic dermatitis. Nat. Rev. Dis. Primers 2018, 4, 1. [Google Scholar] [CrossRef] [PubMed]
- Werfel, T.; Heratizadeh, A.; Niebuhr, M.; Kapp, A.; Roesner, L.M.; Karch, A.; Erpenbeck, V.J.; Lösche, C.; Jung, T.; Krug, N.; et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J. Allergy Clin. Immunol. 2015, 136, 96–103.e9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Torres, T.; Puig, L. Managing Cutaneous Immune-Mediated Diseases during the COVID-19 Pandemic. Am. J. Clin. Dermatol. 2020, 21, 307–311. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- American Academy of Dermatology Association. Managing Your Practice through the COVID-19 Outbreak. Available online: https://www.aad.org/member/practice/managing/coronavirus (accessed on 17 April 2021).
- International Psoriasis Council. Statement on the Coronavirus (COVID-19) Outbreak. Available online: https://www.psoriasiscouncil.org/blog/Statement-on-COVID-19-and-Psoriasis.htm (accessed on 23 February 2021).
- Price, K.; Frew, J.; Hsiao, J.; Shi, V. COVID-19 and immunomodulator/immunosuppressant use in dermatology. J. Am. Acad. Dermatol. 2020, 82, e173–e175. [Google Scholar] [CrossRef]
- Jappe, U.; Beckert, H.; Bergmann, K.-C.; Gülsen, A.; Klimek, L.; Philipp, S.; Pickert, J.; Rauber-Ellinghaus, M.M.; Renz, H.; Taube, C.; et al. Biologics for atopic diseases: Indication, side effect management, and new developments. Allergol. Sel. 2021, 5, 1–25. [Google Scholar] [CrossRef]
Before COVID-19 n = 21 | During COVID-19 n = 21 | |
---|---|---|
mean age of patient ± SD | 37 ± 8 | 37 ± 8 |
women | 5 (24%) | 5 (24%) |
severity of AD | ||
mild (SCORAD < 30) | 6 (29%) | 3 (14%) |
moderate (SCORAD = 40–60) | 8 (38%) | 11 (52%) |
heavy (SCORAD > 60) | 7 (33%) | 8 (38%) |
AD IgE dependent | 21 (100%) | 21 (100%) |
mean value of IgE in serum | 1650 kU/L ± 1098 kU/L | 1540 kU/L ± 1214kU/L |
atopic asthma | 2 (10%) | 2 (10%) |
allergic rhinitis and/or conjunctivitis | 6 (29%) | 6 (29%) |
other concomitant diseases | 3 (14%) | 5 (24%) |
treatment against COVID-19 | ||
antihistamines | 18 (86%) | 19 (90%) |
topical glucocorticosteroids | 9 (43%) | 13 (62%) |
calcineurin inhibitors topically | ||
10 (48%) | 14 (67%) | |
systemic glucocorticosteroid | 5 (24%) add prednisone: 12.5 mg ± 2.5 mg | 9 * (43%) |
4 (19%) add 175 mg ± 50 mg | add 24.5 ± 10 mg | |
cyclosporine | 2 (10%) add 12.5 mg ± 5 mg | 4 (19%) add 175 mg ± 50 mg |
methotrexate | 1 (5%) | 2 (10%) add 12.5 mg ± 5 mg |
dupilumab | 1 (5%) |
Hospitalization for COVID-19 | Patients with AD n = 14 | Control Group n = 17 | p |
---|---|---|---|
mean age of patient ± SD | 47 ± 11 | 50 ± 8 | ns |
women | 6 | 7 | ns |
mean number of days of hospitalization ± SD | 14 ± 4 | 16 ± 7 | ns |
mean O2 saturation on admission | 88.7 ± 1.3 | 86.9 ± 2.4 | ns |
passive oxygen therapy | 14 (100%) | 13 (76%) | <0.05 |
mechanical ventilation | 0 | 3 (18%) | <0.05 |
Treatment | 10 (71%) | 13 (76%) | ns |
remdesivir | 8 (57%) | 12 (71%) | ns |
antibiotics | 14 (100%) | 16 (94%) | ns |
heparin | 1 (7%) | 4 (23%) | <0.05 |
plasma of convalescents dexametazon | 3 (21%) | 5 (29%) | ns |
ibuprofen | 5 (35%) | 7 (41%) | ns |
course of AD | - | - | |
no significant changes compared to the time before infection | 6 (14%) | ||
worsening of itching of the skin | 4 (19%) | ||
new skin changes | 3 (21%) | ||
exacerbation of existing skin changes | 2 (14%) | ||
reduction of skin lesions | 2 (14%) | ||
improvement lasting more than 4 weeks | 7 (50%) | ||
deterioration lasting more than 4 weeks | 1 (7%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Miodońska, M.; Bogacz, A.; Mróz, M.; Mućka, S.; Bożek, A. The Effect of SARS-CoV-2 Virus Infection on the Course of Atopic Dermatitis in Patients. Medicina 2021, 57, 521. https://doi.org/10.3390/medicina57060521
Miodońska M, Bogacz A, Mróz M, Mućka S, Bożek A. The Effect of SARS-CoV-2 Virus Infection on the Course of Atopic Dermatitis in Patients. Medicina. 2021; 57(6):521. https://doi.org/10.3390/medicina57060521
Chicago/Turabian StyleMiodońska, Martyna, Agnieszka Bogacz, Magdalena Mróz, Szymon Mućka, and Andrzej Bożek. 2021. "The Effect of SARS-CoV-2 Virus Infection on the Course of Atopic Dermatitis in Patients" Medicina 57, no. 6: 521. https://doi.org/10.3390/medicina57060521